Repotrectinib Sustains ORR, Safety in Locally Advanced or Metastatic ROS1+ NSCLC

Treatment with repotrectinib continued to produce high and durable responses with a manageable safety profile in patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer who were naïve to a TKI or previously treated with 1 TKI and no chemotherapy.

Related Keywords

South Korea ,Seoul ,Soult Ukpyolsi ,Joseph Fiore ,Byoung Chul Cho ,Cancer Laboratory ,Drug Administration ,Yonsei Cancer Center ,Bristol Myers Squibb ,Yonsei University College Of Medicine ,Lung Cancer ,Chul Cho ,Yonsei University College ,Prescription Drug User Fee ,Point Therapeutics ,Patients With Advanced Solid Tumors ,Repotrectinib ,Nsclc ,Trident 1 ,